Skip to main content
. 2018 Jan 16;124(7):1358–1373. doi: 10.1002/cncr.31125

Figure 5.

Figure 5

(A) Metastatic colorectal cancer to the liver in a 72‐year‐old woman whose tumor had progressed after 4 separate lines of chemotherapy. (B) Comprehensive genomic profiling revealed both ERBB2 (163 copies) and retinoic acid receptor alpha (RARA) (35 copies) amplification as well as multiple untargetable short variant genetic alterations. This tumor responded clinically for 6 months to a combination of trastuzumab and lapatinib, with a significant decrease in serum carcinoembryonic antigen levels.